Literature DB >> 19632887

Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Marina Konopleva1, Yoko Tabe, Zhihong Zeng, Michael Andreeff.   

Abstract

In hematological malignancies, there are dynamic interactions between leukemic cells and cells of the bone marrow microenvironment. Specific niches within the bone marrow microenvironment provide a sanctuary for subpopulations of leukemic cells to evade chemotherapy-induced death and allow acquisition of a drug-resistant phenotype. This review focuses on molecular and cellular biology of the normal hematopoietic stem cell and the leukemia stem cell niche, and of the molecular pathways critical for microenvironment/leukemia interactions. The key emerging therapeutic targets include chemokine receptors (CXCR4), adhesion molecules (VLA4 and CD44), and hypoxia-related proteins HIF-1alpha and VEGF. Finally, the genetic and epigenetic abnormalities of leukemia-associated stroma will be discussed. This complex interplay provides a rationale for appropriately tailored molecular therapies targeting not only leukemic cells but also their microenvironment to ensure improved outcomes in leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632887      PMCID: PMC3640296          DOI: 10.1016/j.drup.2009.06.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  122 in total

1.  Detection of functional haematopoietic stem cell niche using real-time imaging.

Authors:  Yucai Xie; Tong Yin; Winfried Wiegraebe; Xi C He; Diana Miller; Danny Stark; Katherine Perko; Richard Alexander; Joel Schwartz; Justin C Grindley; Jungeun Park; Jeff S Haug; Joshua P Wunderlich; Hua Li; Simon Zhang; Teri Johnson; Ricardo A Feldman; Linheng Li
Journal:  Nature       Date:  2008-12-03       Impact factor: 49.962

2.  CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.

Authors:  Michael Fiegl; Ismael Samudio; Karen Clise-Dwyer; Jared K Burks; Zakar Mnjoyan; Michael Andreeff
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

3.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

4.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

Review 5.  The hematopoietic stem cell in myelodysplasia.

Authors:  Jane L Liesveld; Craig T Jordan; Gordon L Phillips
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

6.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

7.  Histone H2AX is integral to hypoxia-driven neovascularization.

Authors:  Matina Economopoulou; Harald F Langer; Arkady Celeste; Valeria V Orlova; Eun Young Choi; Mingchao Ma; Athanassios Vassilopoulos; Elsa Callen; Chuxia Deng; Craig H Bassing; Manfred Boehm; Andre Nussenzweig; Triantafyllos Chavakis
Journal:  Nat Med       Date:  2009-04-19       Impact factor: 53.440

8.  Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Authors:  Jing Zhang; Jing Wang; Yangang Liu; Harwin Sidik; Ken H Young; Harvey F Lodish; Mark D Fleming
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

9.  Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome.

Authors:  O Lopez-Villar; J L Garcia; F M Sanchez-Guijo; C Robledo; E M Villaron; P Hernández-Campo; N Lopez-Holgado; M Diez-Campelo; M V Barbado; J A Perez-Simon; J M Hernández-Rivas; J F San-Miguel; M-C del Cañizo
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

10.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.

Authors:  KangAe Lee; David Z Qian; Sergio Rey; Hong Wei; Jun O Liu; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-23       Impact factor: 12.779

View more
  73 in total

1.  Osteoblasts protect AML cells from SDF-1-induced apoptosis.

Authors:  Kimberly N Kremer; Amel Dudakovic; Meghan E McGee-Lawrence; Rachael L Philips; Allan D Hess; B Douglas Smith; Andre J van Wijnen; Judith E Karp; Scott H Kaufmann; Jennifer J Westendorf; Karen E Hedin
Journal:  J Cell Biochem       Date:  2014-06       Impact factor: 4.429

2.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

Review 3.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

4.  Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.

Authors:  Olga Blau; Claudia Dorothea Baldus; Wolf-Karsten Hofmann; Gundula Thiel; Florian Nolte; Thomas Burmeister; Seval Türkmen; Ouidad Benlasfer; Elke Schümann; Annette Sindram; Mara Molkentin; Stefan Mundlos; Ulrich Keilholz; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

5.  An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.

Authors:  Bing Z Carter; Po Yee Mak; Xiangmeng Wang; Wenjing Tao; Vivian Ruvolo; Duncan Mak; Hong Mu; Jared K Burks; Michael Andreeff
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

6.  Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells.

Authors:  Monika B Sharma; Lalita S Limaye; Vaijayanti P Kale
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 7.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 8.  Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.

Authors:  Edward Allan Racela Sison; Peter Kurre; Yong-Mi Kim
Journal:  Pediatr Hematol Oncol       Date:  2017-12-06       Impact factor: 1.969

Review 9.  Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Authors:  Catherine Tang; Pamela J Russell; Rosetta Martiniello-Wilks; John E J Rasko; Aparajita Khatri
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

Review 10.  Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.

Authors:  R Shirzad; S Shahrabi; A Ahmadzadeh; K R Kampen; M Shahjahani; N Saki
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.